Kenya to Roll Out Revolutionary HIV Prevention Drug Lenacapavir by 2026

 

By Levin Kiprop

 In a landmark move set to reshape HIV prevention efforts, Kenya has announced it will introduce Lenacapavir (LEN), a revolutionary long-acting injectable drug for HIV prevention, by January 2026. This announcement follows a major endorsement by the World Health Organization (WHO), made during the 13th International AIDS Society (IAS) Conference in Kigali, Rwanda.

Kenya is one of the first countries selected to roll out Lenacapavir, a decision hailed as a significant leap forward in pre-exposure prophylaxis (PrEP) strategies. Unlike traditional oral PrEP that requires daily adherence, Lenacapavir only needs to be administered once every six months, offering a highly effective and discreet alternative for people at high risk of HIV infection.

Lenacapavir works by inhibiting the HIV capsid—a critical protein shell of the virus—thereby blocking its ability to replicate and spread in the body. It is designed specifically for individuals who are HIV-negative but face a high risk of contracting the virus. These include sex workers, people who inject drugs, adolescents and young adults in high-prevalence areas, and people in serodiscordant relationships.

“This is a game-changer,” said Dr. Regina Mwangi of the National AIDS and STI Control Programme (NASCOP). “For the first time, we have an HIV prevention tool that doesn’t require daily action. Lenacapavir gives us a chance to reach populations that have traditionally struggled with adherence.”

The Kenyan Ministry of Health has confirmed that Lenacapavir will be made available through selected hospitals, community-based clinics, and potentially pharmacies. Before receiving the injection, individuals will undergo rapid HIV testing to confirm they are HIV-negative and eligible for the drug.

Kenya’s proactive stance comes at a critical time in the global fight against HIV. In 2024 alone, there were 1.3 million new HIV infections worldwide. Africa remains the most affected continent, home to 65% of the 40.8 million people currently living with HIV.

Experts say Lenacapavir could have a profound impact in Africa, where health systems are often stretched and daily pill regimens pose a challenge. A biannual injection reduces logistical hurdles and promotes higher adherence, especially among mobile populations and those in remote areas.

In addition to its medical benefits, Lenacapavir could also help fight the persistent stigma surrounding HIV prevention. “Daily pills can be a visible marker that exposes people to judgment or suspicion,” said Dr. Mwangi. “With Lenacapavir, prevention becomes private and stigma-free.”

For people like 24-year-old Grace Achieng, a university student in Kisumu, the prospect of just two injections a year is both liberating and empowering. “I want to stay protected, but remembering to take a pill every day is hard. This new drug gives me peace of mind without the daily stress,” she said.

As Kenya prepares to usher in this new chapter in HIV prevention, Lenacapavir represents more than a scientific breakthrough—it offers renewed hope, practical protection, and a pathway to ending the HIV epidemic with dignity and compassion.

ENDS